Details of the Drug

General Information of Drug (ID: DMNYOIX)

Drug Name
Olaratumab
Synonyms LY3012207
Indication
Disease Entry ICD 11 Status REF
Soft tissue sarcoma 2B57 Approved [1]
Non-small-cell lung cancer 2C25.Y Phase 1 [2]
Affected Organisms
Humans and other mammals
ATC Code
L01FX10: Olaratumab
L01FX: Other monoclonal antibodies and antibody drug conjugates
L01F: MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Monoclonal antibody
Sequence
>heavy chain
QLQLQESGPGLVKPSETLSLTCTVSGGSINSSSYYWGWLRQSPGKGLEWIGSFFYTGSTY
YNPSLRSRLTISVDTSKNQFSLMLSSVTAADTAVYYCARQSTYYYGSGNYYGWFDRWDQG
TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF
PAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCP
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYT
LPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKL
TVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
>light chain
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPA
RFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPAFGQGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
ADMET Property
Clearance
The mean clearance of drug is 0.56 L/day []
Half-life
The concentration or amount of drug in body reduced by one-half in 11 days [3]
Metabolism
The drug is metabolized via proteolytic enzymes []
Vd
The volume of distribution (Vd) of drug is 7.7 L []
Cross-matching ID
UNII
TT6HN20MVF
DrugBank ID
DB06043
TTD ID
D09QZS
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Platelet-derived growth factor receptor alpha (PDGFRA) TT8FYO9 PGFRA_HUMAN Modulator [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Soft tissue sarcoma
ICD Disease Classification 2B57
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Platelet-derived growth factor receptor alpha (PDGFRA) DTT PDGFRA 3.46E-01 -0.23 -1.55
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Olaratumab (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Olaratumab and Teriflunomide. Hyper-lipoproteinaemia [5C80] [5]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Olaratumab and Denosumab. Low bone mass disorder [FB83] [6]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Olaratumab and Tecfidera. Multiple sclerosis [8A40] [7]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Olaratumab and Siponimod. Multiple sclerosis [8A40] [8]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Olaratumab and Fingolimod. Multiple sclerosis [8A40] [9]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Olaratumab and Ocrelizumab. Multiple sclerosis [8A40] [10]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Olaratumab and Ozanimod. Multiple sclerosis [8A40] [11]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Olaratumab and Rilonacept. Rheumatoid arthritis [FA20] [12]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Olaratumab and Golimumab. Rheumatoid arthritis [FA20] [13]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Olaratumab when combined with Anthrax vaccine. Sepsis [1G40-1G41] [14]
⏷ Show the Full List of 10 DDI Information of This Drug

References

1 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
2 ClinicalTrials.gov (NCT02377752) A Study of Olaratumab in Japanese Participants With Advanced Cancer. U.S. National Institutes of Health.
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRalpha) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604.
5 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
6 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
7 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
8 Cerner Multum, Inc. "Australian Product Information.".
9 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
10 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
11 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
12 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
13 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
14 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]